Velan/Avego Group Holds 9.88% of Jasper Therapeutics After Kira Merger; Director Resigns
JSPR has more than doubled off its 52-week low of $0.315 on elevated volume (2.0× avg).
Summary
Velan Capital and affiliates report a 9.88% stake in Jasper Therapeutics after its merger with Kira Pharmaceuticals, while director Vishal Kapoor resigns.
Key Events · Ownership and Investor Activity · JSPR
-
Post-Merger Ownership Revealed
Following the Kira merger, Velan Capital Investment Management and related entities report aggregate beneficial ownership of 3,349,547 shares, representing 9.88% of Jasper Therapeutics' 33.2 million outstanding shares.
-
Director Resignation
Effective immediately after the merger closed on July 16, 2026, Vishal Kapoor resigned from the board. He retains 35,013 shares (0.1%), including 30,638 options.
-
Warrant Holdings and Blocker
The group holds 1,234,567 warrants subject to a 9.99% beneficial ownership blocker; without the blocker, their stake would be 11.4%.
-
No Recent Transactions
The filing states no transactions in Jasper securities by the reporting persons in the past 60 days, indicating the reported stakes result from the merger exchange.
Analysis · JSPR · Life Sciences
This amended 13D reveals the post-merger ownership structure of Jasper Therapeutics following its all-stock acquisition of Kira Pharmaceuticals. The Velan/Avego investment group, led by Adam Morgan and Balaji Venkataraman, now controls 9.88% of the combined company, or 3.35 million shares. The filing also discloses the resignation of director Vishal Kapoor, effective upon the merger closing, and provides the updated share count of 33.2 million outstanding. While the merger itself was announced days ago, this filing quantifies the resulting insider stakes and governance shift, which are material for investors assessing the new control dynamics.
At the time of this filing, JSPR was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.8M. The 52-week trading range was $0.32 to $3.48. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.